NVG-222 Solid Tumours Phase I/IIa Clinical Trial
Summary
A Phase I/IIa clinical trial for NVG-222 in solid tumours has been registered in the ISRCTN clinical trial registry. The trial is identified by ISRCTN13633989 and falls under the cancer condition category. This registration entry provides protocol metadata for the investigational treatment study without establishing new compliance obligations.
About this source
GovPing monitors ISRCTN - Cancer Trials for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.
What changed
This document is a clinical trial registry entry for NVG-222, an investigational agent being evaluated in a Phase I/IIa study for solid tumours. The ISRCTN registry records the trial's existence, condition category (Cancer), and registration identifier. No regulatory requirements, safety findings, or compliance obligations are established by this registration entry. The trial is classified as an oncology study under the solid tumours indication.
Related changes
Get daily alerts for ISRCTN - Cancer Trials
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from ISRCTN.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ISRCTN - Cancer Trials publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.